WuXi To Offer Foundation’s Genomic Profiling In China

WuXi has been licensed to perform the FoundationOne® assay, providing the best-in-class genomics platform to biopharmaceuticals in China.

AsianScientist (Oct. 27, 2014) – Foundation Medicine, Inc. and WuXi PharmaTech Inc. have agreed to collaborate to offer Foundation Medicine’s comprehensive genomic profiling to biopharmaceutical companies conducting clinical trials in China.

Under the terms of the collaboration, Foundation Medicine will license and enable WuXi to perform the laboratory component of Foundation Medicine’s FoundationOne® assay at the WuXi Genome Center in Shanghai, the first and only US Food and Drug Administration clinical laboratory improvement amendments (CLIA)-certified facility in China.

Foundation Medicine will offer China-based products and services to global biopharmaceutical partners to support their clinical research and development efforts in China. Financial terms of the collaboration are not being disclosed.

“China is poised to become the second-largest pharmaceutical market within the next few years,” said Dr. Ge Li, chairman and chief executive officer of WuXi. “WuXi has seen rapidly increasing demand for molecular profiling services from biopharmaceutical companies as they scale up R&D operations and early development activities in the region.”

“We are pleased to partner with Foundation Medicine, the recognized global leader in comprehensive genomic profiling and a trusted partner of our customers, to provide best-in-class genomic testing to support targeted oncology therapeutic development in China,” he said.

“The development and use of targeted therapies and comprehensive diagnostic tests in oncology are expected to grow significantly in China,” said Dr. Michael J. Pellini, president and chief executive officer of Foundation Medicine.

Foundation Medicine is working with more than 20 biopharmaceutical companies to provide comprehensive genomic profiling in more than 100 studies in 2014 alone. Publicly announced research partners include AstraZeneca, Eisai, Johnson & Johnson, Novartis and Sanofi.

——–

Source: WuXi PharmaTech.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.

Asian Scientist Magazine is an award-winning science and technology magazine that highlights R&D news stories from Asia to a global audience. The magazine is published by Singapore-headquartered Wildtype Media Group.

Related Stories from Asian Scientist